American Society of Hirudotherapy

Argatroban use in heparin-induced thrombocytopenia

Literature review published in Expert opinion on pharmacotherapy (2008)

Last Updated: November 1, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical LiteratureBoggio et al. · Expert opinion on pharmacotherapy, 2008

Abstract

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a serious, life-threatening complication which occurs in 1-3% of patients receiving heparin. Patients with untreated HIT have an up to 50% risk of developing life- and limb-threatening thromboembolic complications. Treatment is based upon clinical suspicion, stopping heparin therapy and initiation of anticoagulation with a rapidly acting alternative non-heparin anticoagulant, such as argatroban-a hepatically excreted direct thrombin inhibitor which is effective in the treatment of HIT. OBJECTIVE: To summarize the pharmacological and clinical data, and discuss the impact of argatroban in the current treatment of HIT. METHODS: A literature search was performed with the aid of Pubmed and Google. Search parameters of 'argatroban', 'heparin-induced thrombocytopenia' and 'treatment' were input into both search engines. CONCLUSION: Argatroban is a safe and effective treatment for HIT. In patients taking other hepatically cleared medications, lower initial doses may have to be used to avoid over-anticoagulation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsArginineClinical Trials as TopicHeparinHumansLiverPipecolic AcidsSulfonamidesThrombocytopeniaThromboembolism

Summary

This review summarizes pharmacological and clinical data on argatroban, a hepatically cleared direct thrombin inhibitor, as treatment for heparin-induced thrombocytopenia, concluding it is safe and effective, with lower initial doses for patients on other hepatically cleared medications.

Why This Matters for Hirudotherapy

This review summarizes the pharmacological and clinical data for argatroban, a synthetic direct thrombin inhibitor, in the treatment of heparin-induced thrombocytopenia (HIT). Direct thrombin inhibitors represent a class of drugs conceptually inspired by natural leech anticoagulants like hirudin. However, argatroban is a completely synthetic molecule and this article does not mention leeches, hirudotherapy, or the leech secretome at all. Therefore, its relevance to the American Society of Hirudotherapy is essentially nonexistent, serving only as a tangential note on a different type of anticoagulant.

Citation

Reference (Vancouver style)

Boggio LN, Oza VM. Argatroban use in heparin-induced thrombocytopenia. Expert Opin Pharmacother. 2008;9(11):1963-1967. doi:10.1517/14656566.9.11.1963. PMID: 18627333

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.